A. (Arja) ter Elst

Clinical Molecular Biologist in Pathology

A. (Arja) ter Elst
Telephone:
E-mail:
a.ter.elst umcg.nl

Research

  1. 2020
  2. Koopman, B., Groen, H. J. M., Ligtenberg, M. J. L., Grünberg, K., Monkhorst, K., de Langen, A. J., Boelens, M. C., Paats, M. S., Von der Thüsen, J. H., Dinjens, W. N. M., Solleveld, N., Van Wezel, T., Gelderblom, H., Hendriks, L. E., Speel, E-J. M., Theunissen, T. E., Kroeze, L. I., Mehra, N., Piet, B., ... van Kempen, L. (2020). Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations. The Oncologist. https://doi.org/10.1002/onco.13580
  3. Steeghs, E. M. P., Kroeze, L. I., Tops, B. B. J., van Kempen, L. C., Ter Elst, A., Kastner-van Raaij, A. W. M., Hendriks-Cornelissen, S. J. B., Hermsen, M. J. W., Jansen, E. A. M., Nederlof, P. M., Schuuring, E., Ligtenberg, M. J. L., & Eijkelenboom, A. (2020). Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material. BMC Cancer, 20(1), [291]. https://doi.org/10.1186/s12885-020-06785-6
  4. 2019
  5. Eijkelenboom, A., Tops, B. B. J., van den Berg, A., van den Brule, A. J. C., Dinjens, W. N. M., Dubbink, H. J., ter Elst, A., Geurts-Giele, W. R. R., Groenen, P. J. T. A., Groenendijk, F. H., Heideman, D. A. M., Huibers, M. M. H., Huijsmans, C. J. J., Jeuken, J. W. M., van Kempen, L. C., Korpershoek, E., Kroeze, L. I., de Leng, W. W. J., van Noesel, C. J. M., ... Ligtenberg, M. J. L. (2019). Recommendations for the clinical interpretation and reporting of copy number gains using gene panel NGS analysis in routine diagnostics. Virchows Archiv : an International Journal of Pathology, 474(6), 673-680. https://doi.org/10.1007/s00428-019-02555-3
  6. 2018
  7. Kampen, K. R., Scherpen, F. J. G., Mahmud, H., ter Elst, A., Mulder, A. B., Guryev, V., Verhagen, H. J. M. P., De Keersmaecker, K., Smit, L., Kornblau, S. M., & de Bont, E. S. J. M. (2018). VEGFC Antibody Therapy Drives Differentiation of AML. Cancer Research, 78(20), 5940-5948. https://doi.org/10.1158/0008-5472.CAN-18-0250
  8. 2017
  9. 2016
  10. Mahmud, H., Kornblau, S. M., ter Elst, A., Scherpen, F. J. G., Qiu, Y. H., Coombes, K. R., & de Bont, E. S. J. M. (2016). Epidermal growth factor receptor is expressed and active in a subset of acute myeloid leukemia. Journal of Hematology & Oncology, 9(1), [64]. https://doi.org/10.1186/s13045-016-0294-x
  11. 2015
  12. Boleij, A., Tops, B. B. J., Rombout, P. D. M., Dequeker, E. M., Ligtenberg, M. J. L., van Krieken, J. H., & Dutch RAS EQA Initiative (2015). RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers. Oncotarget, 6(17), 15681-15689. https://doi.org/10.18632/oncotarget.3804
  13. 2014
  14. 2013
  15. Mahmud, H., ter Elst, A., Scherpen, F. J. G., Meeuwsen-de Boer, T. G. J., Kampen, K. R., Guryev, V., de Haas, Kornblau, S. M., & de Bont, E. S. J. M. (2013). Kinomics Profiling Of Pediatric Acute Myeloid Leukemia Based On Prognosis. Blood, 122(21).
  16. 2011
  17. Ter Elst, A., Diks, S. H., Kampen, K. R., Hoogerbrugge, P. M., Ruijtenbeek, R., Boender, P. J., Sikkema, A. H., Scherpen, F. J. G., Kamps, W. A., Peppelenbosch, M. P., & de Bont, E. S. J. M. (2011). Identification of new possible targets for leukemia treatment by kinase activity profiling. Leukemia and Lymphoma, 52(1), 122-130. https://doi.org/10.3109/10428194.2010.535181
  18. 2010
  19. de Jonge, H. J. M., Valk, P. J. M., Veeger, N. J. G. M., ter Elst, A., den Boer, M. L., Cloos, J., de Haas, V., van den Heuvel-Eibrink, M. M., Kaspers, G. J. L., Zwaan, C. M., Kamps, W. A., Lowenberg, B., & de Bont, E. S. J. M. (2010). High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. Blood, 116(10), 1747-1754. https://doi.org/10.1182/blood-2010-03-270991
  20. 2009
  21. Sikkema, A. H., Diks, S. H., den Dunnen, W. F. A., ter Elst, A., Scherpen, F. J. G., Hoving, E. W., Ruijtenbeek, R., Boender, P. J., de Wijn, R., Kamps, W. A., Peppelenbosch, M. P., & de Bont, E. S. J. M. (2009). Kinome Profiling in Pediatric Brain Tumors as a New Approach for Target Discovery. Cancer Research, 69(14), 5987-5995. https://doi.org/10.1158/0008-5472.CAN-08-3660
  22. 2008
  23. de Jonge, H. J. M., Weidenaar, A. C., Ter Elst, A., Boezen, H., Scherpen, F. J. G., Bouma-Ter Steege, J. C. A., Kaspers, G. J. L., Goemans, B. F., Creutzig, U., Zimmermann, M., Kamps, W. A., & de Bont, E. S. J. M. (2008). Endogenous vascular endothelial growth factor-C expression is associated with decreased drug responsiveness in childhood acute myeloid leukemia. Clinical Cancer Research, 14(3), 924-930. https://doi.org/10.1158/1078-0432.CCR-07-1821
  24. Weidenaar, A. C., de Jonge, H. J. M., Fidler, V., ter Elst, A., Meeuwsen-de Boer, T., Douwes, J., Bouma-ter Steege, J. C. A., Haehlen, K., Kamps, W. A., de Bont, E. S. J. M., & Hahlen, K. (2008). Addition of PTK787/ZK 222584 can lower the dosage of amsacrine to achieve equal amounts of acute myeloid leukemia cell death. Anti-Cancer Drugs, 19(1), 45-54.
  25. 2007
  26. 2006
  27. ter Elst, A., Hiemstra, B. E., van der Vlies, P., Kamminga, W., van der Veen, A. Y., Davelaar, I., Terpstra, P., Meerman, G. J. T., Gerbens, F., Kok, K., & Buys, C. H. C. M. (2006). Functional analysis of lung tumor suppressor activity at 3p21.3. GENES CHROMOSOMES & CANCER, 45(12), 1077-1093. https://doi.org/10.1002/gcc.20367
  28. Angeloni, D., ter Elst, A., Wei, M. H., van der Veen, A. Y., Braga, E. A., Klimov, E. A., Timmer, T., Korobeinikova, L., Lerman, M. I., & Buys, C. H. C. M. (2006). Analysis of a new homozygous deletion in the tumor suppressor region at 3p12.3 reveals two novel intronic noncoding RNA genes. GENES CHROMOSOMES & CANCER, 45(7), 676-691. https://doi.org/10.1002/gcc.20332
  29. 2005
  30. 1999
  31. Timmer, T., Terpstra, P., van den Berg, A., Veldhuis, PMJF., Ter Elst, A., van der Veen, AY., Kok, K., Naylor, SL., & Buys, CHCM. (1999). An evolutionary rearrangement of the Xp11.3-11.23 region in 3p21.3, a region frequently deleted in a variety of cancers. GENOMICS, 60(2), 238-240.
  32. Timmer, T., Terpstra, P., van den Berg, A., Veldhuis, PMJF., Ter Elst, A., Voutsinas, G., Hulsbeek, MMF., Draaijers, TG., Looman, MWG., Kok, K., Naylor, SL., & Buys, CHCM. (1999). A comparison of genomic structures and expression patterns of two closely related flanking genes in a critical lung cancer region at 3p21.3. European Journal of Human Genetics, 7(4), 478-486.

ID: 181095